<DOC>
	<DOC>NCT00712491</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.</brief_summary>
	<brief_title>Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria include, but are not limited to: Diagnosed with subfoveal choroidal neovascularization secondary to agerelated macular degeneration Visual acuity of 20/50 to 20/200 in study eye Any other ocular disease that could compromise vision in the study eye History of any prior treatment for choroidal neovascularization in the study eye Presence of other causes of choroidal neovascularization other than secondary to agerelated macular degeneration</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>wet AMD</keyword>
	<keyword>CNV</keyword>
</DOC>